Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to ...

Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a positive phase 3 readout. | AstraZeneca and Daiichi Sankyo are gunning to get ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...